Patients with BRCA mutations have improved overall response to platinum-based therapy, which is associated with longer survival in patients with BRCA-mutated ovarian cancer (17, 20).PARP enzymes, especially PARP-1 and PARP-2, play a key role in the repair of DNA single-strand breaks. This evidence concerns the gene PARP1 and ovarian carcinoma.